On Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was 3.79% up from the session before settling in for the closing price of $313.13. A 52-week range for ALNY has been $205.87 – $317.54.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 23.11%. When this article was written, the company’s average yearly earnings per share was at 60.98%. With a float of $124.67 million, this company’s outstanding shares have now reached $130.31 million.
Let’s determine the extent of company efficiency that accounts for 2230 employees. In terms of profitability, gross margin is 86.01%, operating margin of -4.91%, and the pretax margin is -15.13%.
Alnylam Pharmaceuticals Inc (ALNY) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Alnylam Pharmaceuticals Inc stocks. The insider ownership of Alnylam Pharmaceuticals Inc is 4.38%, while institutional ownership is 96.24%. The most recent insider transaction that took place on May 30 ’25, was worth 9,630,902. In this transaction Chief Executive Officer of this company sold 31,640 shares at a rate of $304.39, taking the stock ownership to the 48,948 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Chief Executive Officer sold 19,297 for $306.00, making the entire transaction worth $5,904,882. This insider now owns 48,948 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 60.98% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
You can see what Alnylam Pharmaceuticals Inc (ALNY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.09, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach 1.85 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Looking closely at Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), its last 5-days average volume was 0.88 million, which is a drop from its year-to-date volume of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 80.06%.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 99.14%, which indicates a significant increase from 96.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.55% in the past 14 days, which was lower than the 48.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $278.39, while its 200-day Moving Average is $264.61. However, in the short run, Alnylam Pharmaceuticals Inc’s stock first resistance to watch stands at $330.70. Second resistance stands at $336.40. The third major resistance level sits at $346.77. If the price goes on to break the first support level at $314.63, it is likely to go to the next support level at $304.26. Now, if the price goes above the second support level, the third support stands at $298.56.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are 130,388K outstanding shares of the company, which has a market capitalization of 42.38 billion. As of now, sales total 2,248 M while income totals -278,160 K. Its latest quarter income was 594,190 K while its last quarter net income were -57,480 K.
